MannKind Corp
$ 3.66
-2.40%
12 Jun - close price
- Market Cap 1,130,758,000 USD
- Current Price $ 3.66
- High / Low $ 3.81 / 3.64
- Stock P/E N/A
- Book Value -0.19
- EPS -0.07
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE N/A %
- 52 Week High 6.51
- 52 Week Low 2.23
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Analyst Target Price
$7.59
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-26 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.02 | 0.01 | 0.07 | 0.05 | 0.04 | 0.03 | 0.04 | -0.01 | 0.04 | 0.0043 | 0.01 | -0.02 |
| Estimated EPS | 0.0067 | 0.03 | 0.03 | 0.08 | 0.06 | 0.04 | 0.03 | 0.01 | 0.03 | 0.01 | -0.02 | -0.04 |
| Surprise | -0.0267 | -0.02 | 0.04 | -0.03 | -0.02 | -0.01 | 0.01 | -0.02 | 0.01 | -0.0057 | 0.03 | 0.02 |
| Surprise Percentage | -398.5075% | -66.6667% | 133.3333% | -37.5% | -33.3333% | -25% | 33.3333% | -200% | 33.3333% | -57% | 150% | 50% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNKD
2026-06-13 15:38:55
Wells Fargo recently raised its price target on MannKind Corporation (MNKD) to $11 from $10, reiterating an Overweight rating, following the FDA's approval of Afrezza for pediatric patients. This approval, expanding Afrezza's use to children aged 6 and older with type 1 and type 2 diabetes, positions MannKind with significant commercial potential, termed a "show-me story" by Wells Fargo. MannKind also stands to receive development milestones and royalties from its Tyvaso DPI manufacturing agreement, with its CEO highlighting the company's evolving strength.
2026-06-12 19:08:57
This article highlights MannKind Corporation (NASDAQ:MNKD) as one of seven hidden penny stocks to consider. The biopharmaceutical company recently received FDA approval for its Afrezza Inhalation Powder in pediatric patients and has potential for significant development milestones and royalties. Despite its growth potential, the article suggests that some AI stocks may offer higher returns with less risk.
2026-06-12 02:13:00
MannKind (MNKD) is gaining investor attention after recent positive clinical data for Afrezza and FUROSCIX, alongside pediatric FDA approval for Afrezza. Despite a recent 35.38% share price rebound over 90 days, the year-to-date return is still down 33.04%. The company is considered 47.7% undervalued at its current price of $3.75 compared to a narrative fair value of $7.17, driven by projected accelerated market penetration for Afrezza and progress in its inhaled pipeline.
2026-06-11 22:40:41
MannKind Corporation has received FDA approval to expand the label for its Afrezza inhaled insulin. This expansion now includes children and adolescents aged four to 17 with diabetes, making Afrezza the first inhaled insulin option for a pediatric population. The company plans to continue research to better understand treatment patterns and patient perception in this age group.
2026-06-11 16:39:55
New analyses from the ADA 2026 Scientific Sessions indicate that Afrezza, an inhaled insulin, provides comparable glycemic control, a favorable safety profile, and higher treatment satisfaction in children and adolescents with diabetes. The INHALE-1 study subgroup analyses highlighted its benefits for this age group, including less weight gain and no significant difference in pulmonary function or hypoglycemia compared to subcutaneous insulin. These findings support Afrezza as a valuable option for managing type 1 diabetes in pediatric patients, particularly teenagers, by simplifying insulin administration and offering flexibility.
2026-06-09 06:39:04
The American Diabetes Association (ADA) conference 2026 featured significant readouts in type 1 and type 2 diabetes. Roche's acmopatide showed promise in T1D by reducing A1C levels and insulin requirements while aiding weight loss. MannKind's inhaled insulin Afrezza received FDA approval for pediatric patients and demonstrated improved treatment satisfaction and comparable efficacy to rapid-acting insulin analogues. Amgen's Repatha reduced cardiovascular event risk in high-risk diabetes patients, and Lilly provided detailed data on retatrutide's efficacy in T2D for A1C reduction and metabolic improvements.
